Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 5,232 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: Infections, Cytomegalovirus
Interventions: Blood collection, Urine collection, Saliva collection; Procedure
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 369 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Stevensville, Michigan

Conditions: HIV Infections, Tuberculosis
Interventions: Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Los Angeles, California • Torrance, California • Miami, Florida + 7 more

Conditions: Prosthetic-joint Infection
Interventions: Culturelle Digestive Daily Probiotic Capsule; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Draining Hematoma
Interventions: Standard Pressure Dressing, VAC; Procedure · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Coronavirus Infection
Interventions: SARS-CoV-2 Antibody Analysis, Weck-cel Swab Collection, Web Based Questionnaire; Diagnostic Test · Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Respiratory Syncytial Virus Infection
Interventions: RSV Polyclonal Immunoglobulin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infection
Interventions: Cefazolin 2g for Injection USP and Dextrose Injection USP, Cefazolin 1.5g; Drug
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bacterial Infections
Interventions: Central Venous Catheter; Device
Lead sponsor: Angiotech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 21
States / cities: Birmingham, Alabama • Orange, California • San Diego, California + 17 more

Conditions: Peripheral Arterial Disease, Diabetic Foot, Diabetes Mellitus
Interventions: ABI/WIFI scoring; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Latent Tuberculosis
Interventions: Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cytomegalovirus Infections, HIV Infections, Hypocalcemia
Interventions: Magnesium sulfate, Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: HIV Infections
Interventions: MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Recurrent Urinary Tract Infections
Interventions: Intravesical Heparin, Placebo; Drug · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: CMV
Interventions: Brincidofovir, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 39
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 25 more

Conditions: Hepatitis B
Interventions: Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Indianapolis, Indiana • New Orleans, Louisiana + 6 more

Conditions: Clostridioides Difficile Infection
Interventions: Health counseling sessions, Diet (control diet), Diet (experimental diet); Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hepatitis C Virus
Interventions: ribavirin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Neisseria Gonorrhoeae
Interventions: 1 mg/kg single infusion of F598, 3 mg/kg single infusion of F598, 10 mg/kg single infusion of F598; Drug
Lead sponsor: Alopexx Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pars Plana Vitrectomy, Scleral Buckling, Surgical Outcomes, Infection Prophylaxis
Interventions: Not listed
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Interleukin-12, Paromomycin sulfate, Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ostomy - Ileostomy or Colostomy, Stoma Complications, Stoma Site Dermatitis, Stoma Site Infection, Peristomal Wound Infection, Peristomal Skin Complication, Stomal Bleeding, Stoma Site Incisional Hernia, Retraction of Colostomy, Retraction of Ileostomy, Stoma Malfunction
Interventions: Chromic Gut Suture, Polyglactin 910 Suture; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Aspergillosis, Candidemia, C. Difficile
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Solid Organ Transplant, Viral Infection
Interventions: Viral Specific T-cells (VSTs); Biological
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

A Study in Adolescent Females to Explore Cytomegalovirus Infection

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

The Effect of Peri-Operative Adjunctive Probiotics on Immunological Markers in Cases of Prosthetic Joint Infection of the Hip and Knee

Vacuum Assisted Closure as a Treatment for Draining Hematomas

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida

Prevention of RSV Infections in Bone Marrow Transplant Recipients

Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

Implementation of ABI and WIfI in Rural Health Clinics

Economic Incentives and vDOT for Latent Tuberculosis Infection

Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)

Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection

Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males

Necessity of Post-operative Eye Drops

Treatment of Chronic Cryptosporidiosis in AIDS Patients

Suture Choice for Ostomy Creation

UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients

Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant